KHKia Hakkarainen

Kia Hakkarainen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kia Hakkarainen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hyperuricemia—Especially “Metabolic Hyperuricemia”—Is Independently Associated with a Higher Risk of Steatotic Liver Disease

    by Janis Timsans, Jenni Kauppi, Vappu Rantalaiho, Anne Kerola, Kia Hakkarainen, Mika Paldanius, Hannu Kautiainen, Markku Kauppi

    Background: Hyperuricemia and steatotic liver disease are both associated with various comorbidities and mortality. This study was carried out to study the association between hyperuricemia and steatotic liver disease and to assess the impact of the etiology of hyperuricemia on the development of steatotic liver disease. Methods: Data from a population-based study of 2635 individuals aged 52–76 years was used. Hyperuricemia was defined as a serum urate (SU) of >410 μmol/L (≈6.9 mg/dL; 75th percentile) and steatotic liver disease as a fatty liver index (FLI) of ≥80 (75th percentile). We defined hyperuricemia as renal if estimated glomerular filtration rate (eGFR) was ≤67 mL/min/1.73 m2 (25th percentile) and as metabolic if eGFR was >67 mL/min/1.73 m2. Results: FLI correlated with SU in women [r = 0.47 (95% CI: 0.43 to 0.51)] and men [r = 0.37 (95% CI: 0.32 to 0.42)]. Compared to those with SU ≤ 410 μmol/L and FLI < 80, the hazard ratio (HR) for all-cause mortality was 1.76 (95% CI: 1.39 to 2.23) in hyperuricemic individuals with FLI ≥ 80, 1.16 (95% CI: 0.95 to 1.40) in hyperuricemic individuals with FLI < 80, and 1.34 (95% CI: 1.06 to 1.70) in persons with SU ≤ 410 μmol/L and FLI ≥ 80. Individuals with metabolic hyperuricemia had a statistically significantly higher FLI than individuals with renal hyperuricemia: mean (SD) = 73.4 (12.2) and 69.6 (22.5), respectively, p = 0.015 after adjusting for sex and diabetes. Conclusions: FLI correlates positively with SU, and it is higher in persons with metabolic hyperuricemia. Both steatotic liver disease and hyperuricemia increase mortality.


  • Open Access

    Serum Uric Acid Is Associated with Insulin Resistance in Non-Diabetic Subjects

    by Janis Timsans, Jenni Kauppi, Vappu Rantalaiho, Anne Kerola, Kia Hakkarainen, Tiina Lehto, Hannu Kautiainen, Markku Kauppi

    Background: Glucose metabolism disorders are major contributors to morbidity and mortality. Elevated serum uric acid (SUA) is closely linked to the cardiometabolic consequences of glucose metabolism disorders, various other comorbidities, and mortality. In this study, we explore the relationship between SUA and fasting plasma glucose (FPG), insulin levels, and insulin resistance in an older Finnish adult cohort. Methods: We used data from the GOAL (GOod Ageing in Lahti region) study—a prospective, population-based study of Finnish individuals aged 52–76 years. A total of 2322 non-diabetic subjects were included in the study. Data of SUA, FPG, and other laboratory parameters, comorbidities, lifestyle habits, and socioeconomic factors were collected. Subjects with SUA values of >410 μmol/L (≈6.9 mg/dL; 75th percentile) were regarded as hyperuricemic. We investigated the relationship between SUA and FPG, insulin levels, and insulin resistance [homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.65]. Results: We found statistically significant sex-, age- and BMI-adjusted small to moderate relationships (Cohen’s standard for β values above 0.10 and 0.30, respectively) between SUA and FPG, insulin levels, and insulin resistance in the whole study population as well as in the female and male subgroups. The higher the SUA level, the higher the HOMA-IR [(adjusted β = 0.21 (95% CI: 0.17 to 0.25)], and it rises drastically if SUA is above 400 μmol/L (≈6.7 mg/dL). The probability of a subject having insulin resistance is related to SUA level. Conclusions: Hyperuricemia is associated with elevated FPG and insulin resistance, emphasizing the importance of addressing both conditions. Further research may explore hyperuricemia treatment’s role in preventing glucose metabolism disorders and their cardiometabolic consequences.